SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 7, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that it
is preparing to ship the Diasensor(R)1000 noninvasive glucose sensor
to the United Kingdom.
The Company's European distributor, EuroSurgical, Ltd.,
has been informed of the approval and plans are being implemented by
the two companies to begin a marketing campaign for the sensor in
the UK.
Biocontrol President, David L. Purdy, said, "The
company expects quick orders from EuroSurgical and will make
shipment within the week from immediately available inventory."
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Exhibits - Press Release.
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
DATED: July 6, 1998 Fred E. Cooper, CEO
BICO
<PAGE>
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL PREPARING TO SHIP DIASENSOR 1000 RECENTLY APPROVED FOR
THE EUROPEAN MARKET
Pittsburgh, PA - July 6, 1998 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that it is preparing to ship the
Diasensor(R)1000 noninvasive glucose sensor to the United Kingdom.
As Biocontrol announced on Thursday, July 2, the Company was
awarded approval to apply the CE Mark to the Diasensor. The CE
Mark is recognized worldwide and allows marketing of product in
almost every country of the world except the US.
The Company's European distributor, EuroSurgical, Ltd., has
been informed of the approval and plans are being implemented by
the two companies to begin a marketing campaign for the sensor in
the UK.
Biocontrol President, David L. Purdy, said, "The company
expects quick orders from EuroSurgical and will make shipment
within the week from immediately available inventory."
The application of the CE Mark signifies that the
device meets certain quality conformance standards and safety
requirements in accordance with the Medical Device Directive
established by the EU and that performance an efficacy was proven
by data collected in the company's clinical trials. This level
of product qualification became mandatory on June 14, 1998 for
shipment of medical devices into the EU.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
